Why Mallinckrodt Got Crushed
September 05, 2017 at 16:51 PM EDT
Shares of Mallinckrodt sank more than 12% after the drug maker lost a patent battle over its respiratory treatment Inomax. Is the market overreacting?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.